U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06802081) titled 'TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation' on Jan. 27.
Brief Summary: This is a single center randomized double blind controlled study of patients (BMI> 30 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Study Start Date: March 03
Study Type: INTERVENTIONAL
Condition:
Atrial Fibrillation
Obesity
Intervention:
DRUG: Tirzepatide
Weekly subcutaneous injections starting with dose 2.5mg, then inc...